Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.

ABSTRACT: There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

SUBMITTER: P Daukshus N 

PROVIDER: S-EPMC9989834 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature